Compare Organon Pharma Indonesia Tbk. (SCPI) vs Reksa Dana Indeks Premier ETF FTSE Indonesia ESG (XIFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Reksa Dana Indeks Premier ETF FTSE Indonesia ESG — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Reksa Dana Indeks Premier ETF FTSE Indonesia ESG trades at Rp95 (market cap 31.23B, 9.4K 24h volume). The key difference: Organon Pharma Indonesia Tbk. is far larger — about 3.3× Reksa Dana Indeks Premier ETF FTSE Indonesia ESG's market cap. Which is the better fit depends on your goals.
| SCPI | XIFE | |
|---|---|---|
Market Cap | 104.4B | 31.23B |
Volume | — | 9.4K |
Lot | — | 94 |
Turnover | — | 893K |
Average Price | — | 95 |
Value | — | 893K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
